{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:27:16Z","timestamp":1781738836030,"version":"3.54.5"},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.blre.2019.03.004","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T13:06:06Z","timestamp":1553087166000},"page":"10-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Acquired Glanzmann thrombasthenia: From antibodies to anti-platelet drugs"],"prefix":"10.1016","volume":"36","author":[{"given":"Alan T.","family":"Nurden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2019.03.004_bb0005","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1182\/blood.V75.7.1383.1383","article-title":"Glanzmann's thrombasthenia: the spectrum of clinical disease","volume":"75","author":"George","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0010","doi-asserted-by":"crossref","first-page":"5996","DOI":"10.1182\/blood-2011-07-365635","article-title":"Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models","volume":"118","author":"Nurden","year":"2011","journal-title":"Blood"},{"issue":"Suppl. 4","key":"10.1016\/j.blre.2019.03.004_bb0015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2516.2012.02842.x","article-title":"Treatment of inherited platelet disorders","volume":"18","author":"Seligsohn","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.03.004_bb0020","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/bjh.15409","article-title":"How we treat the platelet glycoprotein defects: Glanzmann thrombasthenia and Bernard-Soulier syndrome in children and adults","volume":"182","author":"Grainger","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.03.004_bb0025","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2017-03-773614","article-title":"Integrin \u03b1IIb\u03b23 outside-in signaling","volume":"130","author":"Durant","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0030","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1161\/ATVBAHA.118.310224","article-title":"Platelet signaling pathways and new inhibitors","volume":"38","author":"Grover","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.blre.2019.03.004_bb0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1242\/jcs.161190","article-title":"The kindlin family: functions, signaling properties and implications for human disease","volume":"129","author":"Rognoni","year":"2016","journal-title":"J Cell Sci"},{"key":"10.1016\/j.blre.2019.03.004_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmrv.2018.05.002","article-title":"Acquired antibodies to \u03b1IIb\u03b23 in Glanzmann thrombasthenia: from transfusion and pregnancy to bone marrow transplants and beyond","author":"Nurden","year":"2018","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.blre.2019.03.004_bb0045","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1055\/s-0038-1648233","article-title":"Alloimmunization in congenital deficiencies of platelet surface glycoproteins: focus on Glanzmann's thrombasthenia and Bernard-Soulier syndrome","volume":"44","author":"Poon","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2019.03.004_bb0050","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2141.2006.06024.x","article-title":"The pathogenesis of immune thrombocytopenic purpura","volume":"133","author":"Cooper","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.03.004_bb0055","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1182\/blood-2009-01-129155","article-title":"The ITP syndrome: pathogenic and clinical diversity","volume":"113","author":"Cines","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0060","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrrheum.2018.38","article-title":"The non-haemostatic role of platelets in systemic lupus erythematosus","volume":"14","author":"Linge","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.blre.2019.03.004_bb0065","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.critrevonc.2011.02.004","article-title":"Paraneoplastic autoimmune thrombocytopenia in solid tumors","volume":"81","author":"Krauth","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.blre.2019.03.004_bb0070","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1055\/s-0034-1371004","article-title":"Immune-mediated disorders causing bleeding or thrombosis in lymphoproliferative diseases","volume":"40","author":"Lechner","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2019.03.004_bb0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1056\/NEJM199101033240106","article-title":"The clinical importance of acquired abnormalities of platelet function","volume":"324","author":"George","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.03.004_bb0080","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMra066469","article-title":"Drug-induced immune thrombocytopenia","volume":"357","author":"Aster","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.03.004_bb0085","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1182\/blood-2008-06-077891","article-title":"The GPIIb\/IIIa (integrin \u03b1IIb\u03b23) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend","volume":"112","author":"Coller","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0090","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/blood.V68.2.571.571","article-title":"Acquired thrombasthenia due to GPIIb-IIIa-specific platelet autoantibodies","volume":"68","author":"Niessner","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0095","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1172\/JCI112270","article-title":"A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with fatal bleeding","volume":"77","author":"DiMinno","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2019.03.004_bb0100","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1046\/j.1365-2141.1996.d01-1957.x","article-title":"A non-thrombocytopenic bleeding disorder due to an IgG4-kappa anti-GPIIb\/IIIa autoantibody","volume":"95","author":"McMillan","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.03.004_bb0105","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1046\/j.1365-2141.2002.03870_4.x","article-title":"The successful use of plasma exchange and immunosuppression in the management of acquired Glanzmann's thrombasthenia","volume":"119","author":"Thomas","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.03.004_bb0110","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.blre.2017.03.005","article-title":"Should studies on Glanzmann thrombasthenia not be telling us more about cardiovascular disease and other major illnesses?","volume":"31","author":"Nurden","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2019.03.004_bb0115","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-0609.2005.00574.x","article-title":"Acquired thrombasthenia due to GPIIbIIIa platelet autoantibodies in a 4-yr-old child","volume":"76","author":"Bloor","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2019.03.004_bb0120","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ajh.22079","article-title":"Acquired Glanzmann's thrombasthenia with optimal response to rituximab therapy","volume":"86","author":"Solh","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2019.03.004_bb0125","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","article-title":"Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab","volume":"112","author":"Stasi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0130","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/bjh.14664","article-title":"The effect of rituximab on anti-platelet autoantibody levels in patients with immune thrombocytopenia","volume":"178","author":"Arnold","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.03.004_bb0135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood.V59.1.23.23","article-title":"Specificity of autoantibodies in autoimmune thrombocytopenia","volume":"59","author":"Van Leeuwen","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0140","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood.V63.2.368.368","article-title":"Autoantibodies against the platelet glycoprotein IIb\/IIIa complex in patients with chronic ITP","volume":"63","author":"Woods","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0145","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1182\/blood.V61.1.209.209","article-title":"Acquired Glanzmann's thrombasthenia","volume":"61","author":"Greaves","year":"1983","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0150","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1055\/s-0038-1648178","article-title":"Acquired disorder of platelet function associated with autoantibodies against GPIIb-IIIa complex","volume":"65","author":"Meyer","year":"1991","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.03.004_bb0155","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1055\/s-0038-1656350","article-title":"Defect of platelet aggregation and adhesion induced by autoantibodies against platelet glycoprotein IIIa","volume":"68","author":"Balduini","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.03.004_bb0160","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood.V82.3.820.820","article-title":"Autoantibodies against the platelet glycoproteins (GP) IIb\/IIIa, Ia\/IIa, and IV and partial deficiency in GPIV in a patient with a bleeding disorder and a defective platelet collagen interaction","volume":"82","author":"Beer","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0165","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1083\/jcb.99.6.2056","article-title":"Platelet-collagen adhesion: inhibition by a monoclonal antibody that binds glycoprotein IIb","volume":"99","author":"Shaddle","year":"1984","journal-title":"J Cell Biol"},{"key":"10.1016\/j.blre.2019.03.004_bb0170","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1423-0410.2008.01093.x","article-title":"Acquired Glanzmann's thrombasthenia caused by glycoprotein IIb\/IIIa autoantibodies of the immunoglobulin G1 (IgG1); IgG2 or IgG4 subclass: a study of 6 cases","volume":"95","author":"Porcelijn","year":"2008","journal-title":"Vox Sang"},{"key":"10.1016\/j.blre.2019.03.004_bb0175","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/(SICI)1096-8652(199802)57:2<164::AID-AJH13>3.0.CO;2-C","article-title":"Autoimmune thrombocytopenic purpura (AITP) and acquired thrombasthenia due to autoantibodies to GP IIb-IIIa in a patient with an unusual platelet membrane glycoprotein composition","volume":"57","author":"Macchi","year":"1998","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2019.03.004_bb0180","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1083\/jcb.201212037","article-title":"Complete integrin headpiece opening in eight steps","volume":"201","author":"Zhu","year":"2013","journal-title":"J Cell Biol"},{"key":"10.1016\/j.blre.2019.03.004_bb0185","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood.V81.5.1284.1284","article-title":"Platelet-associated antibody to glycoprotein IIb\/IIIa from chronic immune thrombocytopenic purpura patients often binds to divalent cation-dependent antigens","volume":"81","author":"Fujisawa","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0190","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1172\/JCI115386","article-title":"Localization of human platelet autoantigens to the cysteine-rich region of glycoprotein IIIa","volume":"88","author":"Kekomaki","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2019.03.004_bb0195","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0301-4622(03)00111-X","article-title":"The disulfide-rich region of platelet glycoprotein (GP) IIIa contains hydrophilic peptide sequences that bind anti-GPIIIa autoantibodies from patients with immune thrombocytopenic purpura","volume":"105","author":"Beardsley","year":"2003","journal-title":"Biophys Chem"},{"key":"10.1016\/j.blre.2019.03.004_bb0200","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2012-02-409995","article-title":"Recognition of highly restricted regions in the \u03b2-propeller region of \u03b1IIb by platelet-associated anti-\u03b1IIb\u03b23 autoantibodies in primary immune thrombocytopenia","volume":"120","author":"Kiyomizu","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0205","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1046\/j.1365-2141.2003.04509.x","article-title":"The IgG subclasses of platelet-associated antibodies directed against platelet glycoproteins IIb\/IIIa in patients with idiopathic thrombocytopenic purpura","volume":"122","author":"Chan","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.03.004_bb0210","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood-2008-02-142125","article-title":"Identification of Fcgamma RIIa as the ITAM-bearing receptor mediating alphaIIbbeta3 outside-in integrin signaling in human platelets","volume":"112","author":"Boylan","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0215","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3324\/haematol.12889.","article-title":"Increased cytotoxic T-lymphocyte mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies","volume":"93","author":"Zhao","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.03.004_bb0220","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1600-0609.2011.01718.x","article-title":"Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP)","volume":"88","author":"Najaoui","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2019.03.004_bb0225","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/blood-2014-06-580084","article-title":"Interleukin 27 inhibits cytotoxic T-lymphocyte-mediated platelet destruction in primary immune thrombocytopenia","volume":"124","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0230","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1182\/blood-2012-04-424648","article-title":"Splenic proliferative lymphoid nodules distinct from germinal centers are sites of autoantigen stimulation in immune thrombocytopenia","volume":"120","author":"Daridon","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0235","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood-2002-05-1475","article-title":"Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro","volume":"102","author":"Chang","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0240","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1182\/blood-2003-08-2672","article-title":"Suppression of in vitro megakaryocyte production by antiplatelet antibodies from adult patients with chronic ITP","volume":"103","author":"McMillan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0245","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2003-01-0275","article-title":"Ultrastructural study shows morphologic features of apoptosis and Para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura","volume":"103","author":"Houwerzijl","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0250","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3324\/haematol.2014.115634","article-title":"Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro","volume":"100","author":"Iraqi","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.03.004_bb0255","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12678","article-title":"Antiplatelet antibody-induced thrombocytopenia does not correlate with megakaryocyte abnormalities in murine immune thrombocytopenia","volume":"88","author":"Guo","year":"2018","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.blre.2019.03.004_bb0260","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/bloodadvances.2016002808","article-title":"An intracytoplasmic \u03b23 Leu718 deletion in a patient with a novel platelet phenotype","volume":"1","author":"Nurden","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2019.03.004_bb0265","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/blood.V72.1.362.362","article-title":"Platelet IgG, IgA, IgM, and albumin: correlation of platelet and plasma concentrations in normal subjects and in patients with ITP or dysproteinemia","volume":"72","author":"George","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0270","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1055\/s-0038-1650702","article-title":"PAICA: a method for characterizing platelet-associated antibodies \u2013 its application to the study of idiopathic thrombocytopenic purpura and to the detection of platelet-bound c7E3","volume":"76","author":"Macchi","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.03.004_bb0275","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1182\/blood.V93.5.1622","article-title":"Labeling of the internal pool of GPIIb-IIIa in platelets by c7E3 fragments (abciximab): flow and endocytic mechanisms contribute to the transport","volume":"93","author":"Nurden","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0280","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1111\/hae.12589","article-title":"Successful use of recombinant factor VIIa in a patient with acquired Glanzmann thrombasthenia","volume":"21","author":"Tuffigo","year":"2015","journal-title":"Hemophilia"},{"key":"10.1016\/j.blre.2019.03.004_bb0285","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/jth.14323","article-title":"A unique phenotype of acquired Glanzmann thrombasthenia due to non-function blocking anti- \u03b1IIb\u03b23 autoantibodies","volume":"17","author":"Akuta","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.03.004_bb0290","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood.V70.1.16.16","article-title":"A human monoclonal autoantibody recognizes a neoantigen on glycoprotein IIIa expressed on stored and activated platelets","volume":"70","author":"Nugent","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0295","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0896-8411(91)90157-8","article-title":"Nucleotide sequence of the human autoantibody 2E7 specific for the platelet integrin IIb heavy chain","volume":"4","author":"Kunicki","year":"1991","journal-title":"J Autoimmun"},{"key":"10.1016\/j.blre.2019.03.004_bb0300","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1182\/blood.V100.4.1388.h81602001388_1388_1398","article-title":"Genetic analyses of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation","volume":"100","author":"Roark","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0305","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1537-2995.2006.01142.x","volume":"47","author":"Jennings","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2019.03.004_bb0310","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1182\/bloodadvances.2018023341","article-title":"High-resolution mapping of the polyclonal immune response to the human platelet alloantigen HPA-1a (PLA1)","volume":"2","author":"Zhi","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2019.03.004_bb0315","first-page":"98","article-title":"Severe platelet dysfunction in a patient with autoantibodies against membrane glycoproteins IIb-IIIa","volume":"17","author":"Balduini","year":"1987","journal-title":"Haemostasis"},{"key":"10.1016\/j.blre.2019.03.004_bb0320","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1769::AID-CNCR25>3.0.CO;2-1","article-title":"Acquired Glanzmann's thrombasthenia associated with Hodgkin's lymphoma: a case report and review of the literature","volume":"82","author":"Malik","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2019.03.004_bb0325","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.clml.2013.10.004","article-title":"Acquired Glanzmann thrombasthenia associated with Hodgkin Lymphoma: rapid reversal of functional platelet defect with ABVD (adriamycin\/bleomycin\/vinblastine\/decarbazine) chemotherapy","volume":"14","author":"Raman","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2019.03.004_bb0330","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3324\/haematol.11934","article-title":"Autoimmune thrombocytopenia in non-Hodgkin's lymphomas","volume":"93","author":"Hauswirth","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.03.004_bb0335","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0049-3848(89)90316-2","article-title":"Autoantibody against platelet glycoprotein IIb-IIIa in a patient with non-Hodgkin's lymphoma","volume":"53","author":"Kubota","year":"1989","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2019.03.004_bb0340","first-page":"243","article-title":"Qualitative and quantitative platelet defect with bleeding symptoms as presenting feature of non-Hodgkins lymphomas","volume":"76","author":"Bertolino","year":"1991","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.03.004_bb0345","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/cyto.b.20396","article-title":"A new case of acquired Glanzmann's thrombasthenia: diagnostic value of flow cytometry","volume":"74B","author":"Giannini","year":"2008","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.blre.2019.03.004_bb0350","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/01.mph.0000183864.56533.d2","article-title":"Acquired Glanzmann's thrombasthenia associated with acute lymphoblastic leukemia","volume":"27","author":"Galambrun","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.blre.2019.03.004_bb0355","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.2004.05173.x","article-title":"Acquired Glanzmann's thrombasthenia without thrombocytopenia: a severe acquired autoimmune bleeding disorder","volume":"127","author":"Tholouli","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.03.004_bb0360","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/j.1365-2362.2009.02194.x","article-title":"Acquired Glanzmann's thrombasthenia associated with hairy cell leukaemia","volume":"39","author":"Kannan","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.blre.2019.03.004_bb0365","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1182\/blood.V55.6.903.903","article-title":"Severe platelet dysfunction in hairy cell leukemia with improvement after splenectomy","volume":"55","author":"Roscove","year":"1980","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0370","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2141.2008.07577.x","article-title":"Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias","volume":"145","author":"Eby","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.03.004_bb0375","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1532\/IJH97.04044","article-title":"Glanzmann thrombasthenia with acute myeloid leukemia successfully treated by bone marrow transplantation","volume":"81","author":"Fujimoto","year":"2005","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2019.03.004_bb0380","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3324\/haematol.2009.015941","article-title":"Hereditary myeloproliferative disorders","volume":"95","author":"Skoda","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.03.004_bb0385","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0390","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1182\/blood.V76.10.2017.2017","article-title":"Analysis of platelet aggregation disorders based on flow cytometric analysis of membrane glycoprotein IIb-IIIa with conformation-specific monoclonal antibodies","volume":"76","author":"Ginsberg","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0395","first-page":"954","article-title":"Combined defect in membrane expression and activation of platelet GPIIb-IIIa complex without primary sequence abnormalities in myeloproliferative disease","volume":"111","author":"Kaplan","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.03.004_bb0400","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1182\/blood-2012-05-431288","article-title":"Dysfunction of the PI3 kinase\/Rap1\/\u03b1IIb\u03b23 pathway underlines ex vivo hypoactivity in essential thrombocythemia","volume":"121","author":"Moore","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0405","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/MBC.0b013e3283177b03","article-title":"Resolution of platelet function defects in a patient with chronic myeloid leukemia in chronic phase","volume":"20","author":"Ng","year":"2009","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.blre.2019.03.004_bb0410","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/09537104.2017.1384539","article-title":"Reversal of Glanzmann thrombasthenia platelet phenotype after imatinib treatment in a pediatric chronic myeloid leukemia patient","volume":"29","author":"Chauhan","year":"2018","journal-title":"Platelets"},{"key":"10.1016\/j.blre.2019.03.004_bb0415","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.2174\/1381612822666160226132630","article-title":"Targeting kinases in cancer therapies: adverse effects on blood therapies","volume":"22","author":"Levade","year":"2016","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.blre.2019.03.004_bb0420","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2004-06-2108","article-title":"Increased peripheral platelet destruction and caspase-3-independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients","volume":"105","author":"Houwerzijl","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0425","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/cncr.22602","article-title":"The incidence and impact of thrombocytopenia in myelodysplastic syndromes","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2019.03.004_bb0430","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1074\/mcp.M112.023168","article-title":"Platelet proteome analysis reveals integrin-dependent aggregation defects in patients with myelodysplastic syndromes","volume":"12","author":"Fr\u00f6bel","year":"2013","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.blre.2019.03.004_bb0435","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/humu.22776","article-title":"Expanding the mutation spectrum of the \u03b1IIb\u03b23 integrin in Glanzmann thrombasthenia: screening of the ITGA2B and ITGB3 genes in a large international cohort","volume":"36","author":"Nurden","year":"2015","journal-title":"Hum Mutat"},{"key":"10.1016\/j.blre.2019.03.004_bb0440","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/gcc.20764","article-title":"The role of chromosome 21 in hematology and oncology","volume":"49","author":"Fonatsch","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.blre.2019.03.004_bb0445","first-page":"387","article-title":"Hematopoietic disorders in down syndrome","volume":"1","author":"Choi","year":"2008","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.blre.2019.03.004_bb0450","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejmg.2016.01.006","article-title":"Constitutional abnormalities of chromosome 21 predispose to iAMP21-acute lymphoblastic leukemia (ALL)","volume":"59","author":"Harrison","year":"2016","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.blre.2019.03.004_bb0455","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2009-04-215368","article-title":"The spectrum of Evans syndrome in adults: new insights into the disease based on the analysis of 68 cases","volume":"114","author":"Michel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0460","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000040816","article-title":"Overproduction of antiplatelet antibody against glycoprotein IIb after splenectomy in a patient with Evans syndrome resulting in acquired thrombasthenia","volume":"99","author":"Fuse","year":"1998","journal-title":"Acta Haematol"},{"key":"10.1016\/j.blre.2019.03.004_bb0465","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1046\/j.1365-2141.1997.2103027.x","article-title":"Lupus anticoagulant: strong association with the major histocompatibility complex class II and platelet antibodies","volume":"98","author":"Panzer","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.03.004_bb0470","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1055\/s-0037-1615686","article-title":"Beta2-glycoprotein I binding to platelet microparticle membrane specifically reduces immunoreactivity of glycoprotein IIb\/IIIa","volume":"85","author":"Vallar","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.03.004_bb0475","doi-asserted-by":"crossref","first-page":"566","DOI":"10.4065\/81.4.566-a","article-title":"Clinical remission of acquired thrombasthenia with low-dose methotrexate in a patient with systemic lupus erythematosus","volume":"81","author":"Yee","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2019.03.004_bb0480","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.autrev.2018.01.012","article-title":"Systemic lupus erythematosus and systemic sclerosis: all roads lead to platelets","volume":"17","author":"Scherlinger","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.blre.2019.03.004_bb0485","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2003-07-2367","article-title":"Platelet-associated CD145 in immune thrombocytopenic purpura","volume":"105","author":"Solanilla","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0490","doi-asserted-by":"crossref","unstructured":"Duffau P, Seneschal J, Nicco C, Richez C, Lazaro E, Douchet I, et al. Platelet CD154 potentiates interferon-\u03b1 secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Sci Transl Med 2010;2(47):47ra63. doi: 1126\/scitranslmed.3001001.","DOI":"10.1126\/scitranslmed.3001001"},{"key":"10.1016\/j.blre.2019.03.004_bb0495","first-page":"307","article-title":"Acquired thrombasthenia due to inhibitory effect of glycoprotein IIbIIIa autoantibodies","volume":"16","author":"Blickstein","year":"2014","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.blre.2019.03.004_bb0500","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jpeds.2003.12.040","article-title":"Acquired Glanzmann's thrombasthenia as part of multiple-autoantibody syndrome in a pediatric heart transplant patient","volume":"144","author":"Rawal","year":"2004","journal-title":"J Pediatr"},{"key":"10.1016\/j.blre.2019.03.004_bb0505","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/pbc.20761","article-title":"Acquired immune thrombocytopenias post-cardiac transplantation respond to rituximab","volume":"48","author":"Tubman","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2019.03.004_bb0510","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1055\/s-0037-1615580","article-title":"Acquired Glanzmann's thrombasthenia variant and immune thrombocytopenia in a renal transplant recipient receiving tacrolimus","volume":"94","author":"Morath","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.03.004_bb0515","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrmicro3269","article-title":"Platelets: at the nexus of antimicrobial defence","volume":"12","author":"Yeaman","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.blre.2019.03.004_bb0520","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1160\/TH16-04-0300","article-title":"The prowess of platelets in immunity and inflammation","volume":"116","author":"Koenen","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.03.004_bb0525","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bjh.14653","article-title":"Platelets: much more than bricks in a breached wall","volume":"178","author":"Mancuso","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.03.004_bb0530","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2741\/4613","article-title":"The biology of the platelet with special reference to inflammation, wound healing and immunity","volume":"23","author":"Nurden","year":"2018","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.blre.2019.03.004_bb0535","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1182\/blood.V80.1.162.162","article-title":"Presence of cross-reactive antibody between human immunodeficiency virus (HIV) and platelet glycoproteins in HIV-related immune thrombocytopenic purpura","volume":"80","author":"Bettaieb","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0540","doi-asserted-by":"crossref","first-page":"7589","DOI":"10.1073\/pnas.94.14.7589","article-title":"GPIIIa-(49-66) is a major pathophysiologically relevant antigenic determinant for anti-platelet GPIIIa of HIV-1-related immunologic thrombocytopenia","volume":"94","author":"Nardi","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2019.03.004_bb0545","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2008-09-181073","article-title":"Role of molecular mimicry of hepatitis C virus (HCV) protein with platelet GPIIIa in hepatitis-C related immunologic thrombocytopenia","volume":"113","author":"Zhang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0550","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0092-8674(01)00477-9","article-title":"Complement-independent, peroxidase-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia","volume":"106","author":"Nardi","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.blre.2019.03.004_bb0555","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1074\/jbc.M705902200","article-title":"Platelet fragmentation requires a specific structural conformation of human monoclonal antibody against beta3 integrin","volume":"283","author":"Li","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2019.03.004_bb0560","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1160\/TH11-03-0153","article-title":"The inhibition effect of anti-GPIIIa49-66 antibody on megakaryocyte differentiation","volume":"106","author":"Pan","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.03.004_bb0565","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1182\/blood-2013-11-540526","article-title":"Amplification of bacteria-induced platelet activation is triggered by Fc\u03b3RIIA, integrin \u03b1IIb\u03b23, and platelet factor 4","volume":"123","author":"Arman","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0570","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2008-07-167155","article-title":"Effects of eradication of helicopter pylori infection in patients with immune thrombocytopenic purpura. A systematic review","volume":"113","author":"Stasi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0575","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0887-7963(93)70145-5","article-title":"Immune thrombocytopenia associated with antibiotics","volume":"7","author":"Garratty","year":"1993","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.blre.2019.03.004_bb0580","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1182\/asheducation-2009.1.153","article-title":"Drug-induced thrombocytopenia: pathogenesis, evaluation, and management","author":"George","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2019.03.004_bb0585","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tmrv.2013.05.005","article-title":"Approach to the diagnosis and management of drug-induced immune thrombocytopenia","volume":"27","author":"Arnold","year":"2013","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.blre.2019.03.004_bb0590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbi.2018.01.015","article-title":"Drug-induced thrombocytopenia: focus on platelet apoptosis","volume":"284","author":"De Silva","year":"2018","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.blre.2019.03.004_bb0595","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3181\/00379727-152-39458","article-title":"Effects of penicillin G and cephalothin on platelet function in vivo","volume":"152","author":"Cazenave","year":"1976","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.blre.2019.03.004_bb0600","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1172\/JCI109181","article-title":"Absence of the platelet receptor for drug-dependent antibodies in the Bernard-Soulier syndrome","volume":"62","author":"Kunicki","year":"1978","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2019.03.004_bb0605","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1182\/blood.V72.4.1155.1155","article-title":"Heterogeneity of drug-dependent platelet antigens and their antibodies in quinine- and quinidine-induced thrombocytopenia: involvement of glycoproteins Ib, IIb, IIIa, and IX","volume":"72","author":"Pfueller","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0610","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/blood-2006-01-009803","article-title":"Patients with quinine-induced immune thrombocytopenia have both \u201cdrug-dependent\u201d and \u201cdrug-specific\u201d antibodies","volume":"108","author":"Bougie","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0615","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1182\/blood-2008-09-177279","article-title":"Quinine-dependent, platelet-reactive monoclonals mimic antibodies found in patients with quinine-induced immune thrombocytopenia","volume":"113","author":"Bougie","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0620","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood-2015-04-639351","article-title":"Structural basis for quinine-dependent antibody binding to platelet integrin \u03b1IIb\u03b23","volume":"126","author":"Zhu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0625","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1182\/blood-2007-09-112680","article-title":"Fine specificity of drug-dependent antibodies reactive with a restricted domain of platelet GPIIIa","volume":"111","author":"Peterson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0630","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1182\/blood.V75.2.518.518","article-title":"Vancomycin-dependent antibodies associated with thrombocytopenia and refractoriness to platelet transfusion in patients with leukemia","volume":"75","author":"Christie","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0635","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1182\/blood.V82.10.3075.3075","article-title":"Severe thrombocytopenia in an acquired immunodeficiency syndrome patient associated with pentamidine-dependent antibodies specific for glycoprotein IIb\/IIIa","volume":"82","author":"Christie","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0640","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1182\/blood-2017-10-812461","article-title":"Patients treated with oxiplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies","volume":"131","author":"Curtis","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0645","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.thromres.2011.11.054","article-title":"Heparin modulates the conformation and signaling of platelet integrin \u03b1IIb\u03b23","volume":"129","author":"Yagi","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2019.03.004_bb0650","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1161\/01.ATV.19.12.2835","article-title":"Platelet glycoprotein inhibitors: basic and clinical aspects","volume":"19","author":"Nurden","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.blre.2019.03.004_bb0655","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1160\/TH16-12-0911","article-title":"Platelet receptors as therapeutic targets: past, present and future","volume":"117","author":"Jamasbi","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.03.004_bb0660","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1161\/CIRCRESAHA.112.300570","article-title":"Integrin \u03b1IIb\u03b23: from discovery to efficacious therapeutic target","volume":"112","author":"Bledzka","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.blre.2019.03.004_bb0665","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1160\/TH09-08-0603","article-title":"Thrombocytopenia after abciximab use results from different mechanisms","volume":"103","author":"Lajus","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.03.004_bb0670","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1182\/blood-2012-01-406322","article-title":"Antibodies causing thrombocytopenia in patients with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of \u03b1IIb\/\u03b23 integrin","volume":"119","author":"Bougie","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0675","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1182\/blood-2009-02-203034","article-title":"Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia","volume":"114","author":"Greinacher","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0680","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1111\/jth.13803","article-title":"An \u03b1IIb\u03b23 antagonist prevents thrombosis without causing Fc receptor \u03b3-chain IIa-mediated thrombocytopenia","volume":"115","author":"Kuo","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.03.004_bb0685","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1172\/JCI36745","article-title":"Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain","volume":"119","author":"Gao","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2019.03.004_bb0690","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/ATVBAHA.114.303411","article-title":"Targeting integrin and integrin signaling in treating thrombosis","volume":"35","author":"Estevez","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.blre.2019.03.004_bb0695","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.blre.2017.07.004","article-title":"Platelet populations and priming in hematological diseases","volume":"31","author":"Baaten","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2019.03.004_bb0700","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1182\/blood-2007-11-123620","article-title":"Inflammation induces hemorrhage in thrombocytopenia","volume":"111","author":"Goerge","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0705","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1182\/blood-2018-03-742668","article-title":"Mechanisms of receptor shedding in platelets","volume":"132","author":"Montagu","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0710","doi-asserted-by":"crossref","first-page":"e256","DOI":"10.3324\/haematol.2017.182162","article-title":"The contribution of platelet glycoprotein receptors to inflammatory bleeding prevention is stimulus and organ dependent","volume":"103","author":"Rayes","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.03.004_bb0715","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.tracli.2018.06.005","article-title":"Spontaneous bleeding in thrombocytopenia: is it really spontaneous?","volume":"25","author":"Ho-Tin-No\u00e9","year":"2018","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.blre.2019.03.004_bb0720","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0002-9343(80)90383-6","article-title":"Acquired platelet function due to the circulation of \u201cexhausted\u201d platelets","volume":"69","author":"Pareti","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2019.03.004_bb0725","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/0277-5379(84)90161-5","article-title":"Exhausted platelets in patients with solid tumors without evidence of active consumption coagulopathy","volume":"20","author":"Boneu","year":"1984","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.blre.2019.03.004_bb0730","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1182\/blood-2009-01-200345","article-title":"Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function","volume":"114","author":"Schoenwaelder","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0735","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/blood-2010-01-261669","article-title":"Procoagulant platelets: are they necrotic?","volume":"116","author":"Jackson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0740","doi-asserted-by":"crossref","first-page":"E1550","DOI":"10.1073\/pnas.1720553115","article-title":"Platelets release pathogenic serotonin and return to circulation after immune-complex-mediated sequestration","volume":"115","author":"Cloutier","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2019.03.004_bb0745","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1182\/blood-2015-02-628461","article-title":"Platelet function tests independent of platelet count, are associated with bleeding severity in ITP","volume":"126","author":"Frelinger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0750","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1160\/TH17-06-0387","article-title":"Platelet function in ITP, independent of platelet count, is consistent over time and is associated with both current and subsequent bleeding severity","volume":"118","author":"Frelinger","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.03.004_bb0755","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.tracli.2018.07.003","article-title":"Inherited platelet disorders: management of the bleeding risk","volume":"25","author":"Dupuis","year":"2018","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.blre.2019.03.004_bb0760","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0765","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjh.14515","article-title":"State of the art \u2013 how I manage immune thrombocytopenia","volume":"177","author":"Cooper","year":"2017","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2019.03.004_bb0770","doi-asserted-by":"crossref","DOI":"10.3390\/jcm6020016","volume":"6","author":"Zufferey","year":"2017","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2019.03.004_bb0775","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood-2005-06-009761","article-title":"Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIb\u03b1 antibodies","volume":"108","author":"Webster","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0780","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/jth.12524","article-title":"Association of autoantibody specificity and response to intravenous inmmunoglobulin G therapy in immune thrombocytopenia: a multicenter study","volume":"12","author":"Peng","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.03.004_bb0785","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1038\/ncomms8737","article-title":"Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia","volume":"6","author":"Li","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2019.03.004_bb0790","doi-asserted-by":"crossref","first-page":"E1898","DOI":"10.1073\/pnas.1422238112","article-title":"\u03b1IIb\u03b23 variants defined by next-generation sequencing: predicting variants likely to cause Glanzmann thrombasthenia","volume":"112","author":"Buitrago","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2019.03.004_bb0795","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood.V98.1.130","article-title":"Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura","volume":"98","author":"Kuwana","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0800","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1182\/blood-2002-07-2157","article-title":"Suppression of autoreactive T-cell response to glycoprotein IIb\/IIIa by blockade of CD40\/CD154 interaction: implications for treatment of immune thrombocytopenic purpura","volume":"101","author":"Kuwana","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0805","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/art.10856","article-title":"A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis","volume":"48","author":"Boumpas","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2019.03.004_bb0810","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13075-015-0757-4","article-title":"CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study","volume":"17","author":"Shock","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.blre.2019.03.004_bb0815","doi-asserted-by":"crossref","unstructured":"Qureshi OS, Rowley TF, Junker F, Peters SJ, Crilly S, Compson J, et al. Multivalent Fc\u03b3-receptor engagement by a hexameric Fc-fusion protein triggers Fc\u03b3-receptor internalization and modulation of Fc\u03b3-receptor functions. Sci Rep 2017; 7(1):17049. doi:1038\/s41598-017-17255-17258.","DOI":"10.1038\/s41598-017-17255-8"},{"key":"10.1016\/j.blre.2019.03.004_bb0820","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.11.041","article-title":"Engineered sialylation of pathogenic antibodies in vivo attenuates autoimmune disease","volume":"172","author":"Pagan","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.blre.2019.03.004_bb0825","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/S0140-6736(09)60255-5","article-title":"New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura","volume":"373","author":"Nurden","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2019.03.004_bb0830","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/leu.2010.45","article-title":"Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP","volume":"24","author":"Koehrer","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2019.03.004_bb0835","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2141.2011.08825.x","article-title":"Salvage therapy of autoimmune thrombocytopenic purpura revealing non-Hodgkin lymphoma by the thrombopoietin receptor agonist romiplostim","volume":"156","author":"Al-Nawakil","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.03.004_bb0840","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/1076029610379397","article-title":"Acquired platelet dysfunction in 109 patients from a tertiary care referral hospital","volume":"17","author":"Sharma","year":"2011","journal-title":"Clinn Appl Thromb-Hemost"},{"key":"10.1016\/j.blre.2019.03.004_bb0845","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/bjh.13861","article-title":"Identification of novel biomarkers in chronic immune thrombocytopenia (ITP) by microarray-based serum protein profiling","volume":"172","author":"Bal","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.03.004_bb0850","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1182\/blood-2015-07-607937","article-title":"Megakaryocyte- and megakaryocyte precursor-related gene therapies","volume":"127","author":"Wilcox","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0855","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1182\/blood-2004-12-4619","article-title":"Therapeutic expression of the platelet-specific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia","volume":"106","author":"Fang","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0860","doi-asserted-by":"crossref","first-page":"9583","DOI":"10.1073\/pnas.1016394108","article-title":"Platelet gene therapy improves hemostatic function for integrin alphaIIbbeta3-deficient dogs","volume":"108","author":"Fang","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2019.03.004_bb0865","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/bjh.15085","article-title":"PDC1 and CTLA4 polymorphisms affect the susceptibility to, and clinical features of, chronic immune thrombocytopenia","volume":"180","author":"Kasamatsu","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.03.004_bb0870","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/blood-2007-03-079913","article-title":"Copy number variation of the activating FCGRC2 gene predisposes to idiopathic thrombocytopenic purpura","volume":"111","author":"Breunis","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.004_bb0875","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/bloodadvances.2016001453","article-title":"TGF-\u03b21 along with other platelet contents augments Treg cells to suppress anti-FVIII immune responses in hemophilia A mice","volume":"1","author":"Haribhai","year":"2016","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2019.03.004_bb0880","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1055\/s-0037-1612660","article-title":"Anti-alphavbeta3 antibodies in chronic immune thrombocytopenic purpura","volume":"85","author":"Kosgui","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.03.004_bb0885","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/jth.14214","article-title":"Autoantibody against integrin \u03b1v\u03b23 contributes to thrombocytopenia by blocking the migration and adhesion of megakaryocytes","volume":"16","author":"Zeng","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.03.004_bb0890","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/jth.14227","article-title":"Risk factors for bleeding, including platelet count threshold, in newly diagnosed thrombocytopenia adults","volume":"16","author":"Piel-Julian","year":"2018","journal-title":"J Thromb Haemost"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X19300025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X19300025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:22:05Z","timestamp":1759436525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X19300025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":178,"alternative-id":["S0268960X19300025"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2019.03.004","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acquired Glanzmann thrombasthenia: From antibodies to anti-platelet drugs","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2019.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}